Literature DB >> 11807708

High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection.

W Garrett Nichols1, Lawrence Corey, Ted Gooley, Chris Davis, Michael Boeckh.   

Abstract

The impact of cytomegalovirus (CMV) serostatus (seropositive [(+)] or seronegative [(-)]) of the donor (D) and recipient (R) on mortality after allogeneic non-T cell-depleted stem cell transplantation (SCT) in the era of preemptive therapy was assessed among 1750 patients by means of multivariable Cox regression models. In an analysis that included only pre-SCT variables, D(+)/R(+) and D(+)/R(-) patients had the highest risk for mortality. After neutropenia or the occurrence of CMV disease was controlled for, only D(+)/R(-) patients remained at a significantly higher risk for mortality. Mortality due to bacteremia or invasive fungal infection was higher among D(+)/R(-) (18.3%) than D(-)/R(-) (9.7%) patients (P <.001). Thus, CMV serostatus remains associated with mortality; neutropenia due to ganciclovir administration and CMV disease explain the association with mortality among seropositive recipients. However, in D(+)/R(-) subjects, mortality appears to be associated with bacterial and fungal infection, indicating a possible immunomodulatory effect of primary CMV infection that was undetected despite intensive monitoring.

Entities:  

Mesh:

Year:  2002        PMID: 11807708     DOI: 10.1086/338624

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  112 in total

1.  Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.

Authors:  Margaret L Green; Wendy Leisenring; Daniel Stachel; Steven A Pergam; Brenda M Sandmaier; Anna Wald; Lawrence Corey; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-07       Impact factor: 5.742

2.  Cytomegalovirus infection according to cell source after hematopoietic cell transplantation in pediatric patients.

Authors:  Eun Sang Yi; Yae-Jean Kim
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

Review 3.  How we treat cytomegalovirus in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh; Per Ljungman
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

4.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

5.  Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.

Authors:  Mary K Wloch; Larry R Smith; Souphaphone Boutsaboualoy; Luane Reyes; Christina Han; Jackie Kehler; Heather D Smith; Linda Selk; Ryotaro Nakamura; Janice M Brown; Thomas Marbury; Anna Wald; Alain Rolland; David Kaslow; Thomas Evans; Michael Boeckh
Journal:  J Infect Dis       Date:  2008-06-15       Impact factor: 5.226

Review 6.  The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Miriam Ciáurriz; Amaya Zabalza; Lorea Beloki; Cristina Mansilla; Estela Pérez-Valderrama; Mercedes Lachén; Eva Bandrés; Eduardo Olavarría; Natalia Ramírez
Journal:  Cell Mol Life Sci       Date:  2015-07-15       Impact factor: 9.261

Review 7.  Priorities for CMV vaccine development.

Authors:  Philip R Krause; Stephanie R Bialek; Suresh B Boppana; Paul D Griffiths; Catherine A Laughlin; Per Ljungman; Edward S Mocarski; Robert F Pass; Jennifer S Read; Mark R Schleiss; Stanley A Plotkin
Journal:  Vaccine       Date:  2013-10-13       Impact factor: 3.641

8.  Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status.

Authors:  Raphael Carapito; Ismail Aouadi; Angélique Pichot; Perrine Spinnhirny; Aurore Morlon; Irina Kotova; Cécile Macquin; Véronique Rolli; Anne Cesbron; Katia Gagne; Machteld Oudshoorn; Bronno van der Holt; Myriam Labalette; Eric Spierings; Christophe Picard; Pascale Loiseau; Ryad Tamouza; Antoine Toubert; Anne Parissiadis; Valérie Dubois; Catherine Paillard; Myriam Maumy-Bertrand; Frédéric Bertrand; Peter A von dem Borne; Jürgen H E Kuball; Mauricette Michallet; Bruno Lioure; Régis Peffault de Latour; Didier Blaise; Jan J Cornelissen; Ibrahim Yakoub-Agha; Frans Claas; Philippe Moreau; Dominique Charron; Mohamad Mohty; Yasuo Morishima; Gérard Socié; Seiamak Bahram
Journal:  Bone Marrow Transplant       Date:  2020-04-14       Impact factor: 5.483

Review 9.  Acceleration of allograft failure by cytomegalovirus.

Authors:  Daniel N Streblow; Susan L Orloff; Jay A Nelson
Journal:  Curr Opin Immunol       Date:  2007-08-22       Impact factor: 7.486

Review 10.  Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants.

Authors:  Ellen Meijer; Greet J Boland; Leo F Verdonck
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.